Project Details
Description
RPC01-3203: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
| Status | Active |
|---|---|
| Effective start/end date | 2/1/18 → 12/31/24 |
Funding
- CELGENE CORPORATION
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.